The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy

Nephrology Dialysis Transplantation

Volumn 19, Issue 4, 2004, Pages 940-944

  Zaltzman, Jeffrey S ^a   Nash, Michelle ^a   Chiu, Rick ^a   Prasad, Ramesh ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Allograft nephropathy; Angiotensin receptor antagonists; Angiotensin converting enzyme inhibitors

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAMIPRIL; RAPAMYCIN; TACROLIMUS; VASODILATOR AGENT;

ADULT; AGED; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECIPIENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECEPTORS, ANGIOTENSIN; TIME FACTORS;

EID: 1842471108     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg593     Document Type: Review

References (22)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
2. GISEN Group (Gruppo Italiano di Sudi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
4. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist ibesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
5. Parving HH, Lehnert H, Brochner-Mortensen B, Gomis R, Andersen S, Arner P. The effect of ibesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
6. Bostom AD, Brown RS, Jr, Chavers BM et al. Prevention of post-transplant cardiovascular disease. Report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491-500
7. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II receptor antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58-63
8. Midtvedt K, Hartmann A. Hypertension after kidney transplantation: Are treatment guidelines emerging? Nephrol Dial Transplant 2002; 17: 1166-1169
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from the serum creatinine. Nephron 1976; 16: 31-41
10. Benediktsson H, Chea R, Davidoff A, Paul LC. Antihypertensive drug treatment in chronic renal allograft rejection in the rat: Effect on structure and function. Transplantation 1996; 62: 1634-1642
11. Szabo A, Lutz J, Schleimer K et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982-991
12. Smit van Oosten AS, Navis G, Stegeman CA et al. Chronic blockade of angiotensin II action prevents glomerulosclerosis but induces graft vasculopathy in experimental kidney transplantation. J Pathol 2001; 94: 122-129
13. Noris M, Azzollini N, Pezzotta A et al. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 2001; 12: 1937-1946
14. Midtvedt K, Hartmann A, Holdaas H, Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: A double-blind randomized comparative trial. Clin Transplant 2001; 15: 426-431
15. Lin J, Valeri AM, Markowitz GS, d'Agati VD, Cohen DJ, Radhakrishnan J. Angiotensin-converting enzyme inhibition in chronic renal allograft nephropathy. Transplantation 2002; 73: 783-788
16. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenrich S, Rahn K. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862-868
17. Traindl O, Falger S, Reading S et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55: 1309-1313
18. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167-181
19. Hunsicker LG, Bennett LE. Design of trials of methods to reduce late renal allograft loss: The price of success. Kidney Int 1995; 48 [Suppl 52]: S120-S123
20. Hausberg M, Kosch M, Hohage H et al. Antihypertensive treatment in renal transplant patients - is there a role for ACE inhibitors? Ann Transplant 2001; 6: 31-37
21. 1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 [Suppl 1]: 117-120
22. Remuzzi G, Norberto P. Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hypertens 2002; 11: 1-10